US-toy giant Mattel has reached a settlement in a Federal Court case alleging its Mecard toys infringed on a patent for a toy transformation mechanism owned by Canadian toy company Spin Master.
Dairy giant Parmalat has come up short in its attempt to block competitor The a2 Milk Company from registering a trade mark in Australia for a logo featuring the words “A2/A2 Genetics Verification”.
Generic drug maker Sandoz has secured a retroactive licence to manufacture a cheaper version of top-selling antidepressant Lexapro, the drug at the heart of a long-running patent infringement battle with pharmaceutical giant Lundbeck.
Racing Victoria has dragged fantasy sports gambling company PlayUp to court for allegedly infringing its ‘Best Bets’ trade marks.
Australia’s largest intellectual property services firm IPH will maintain its dominance after winning a takeover battle for Xenith IP, a deal that will create a formidable IP services giant with over 1,000 employees across Asia Pacific.
A judge has denied Mylan’s bid to temporarily block Sun Pharma and Cipla from making generic versions of anti-cholesterol drug Lipidil while it appeals a ruling invalidating several claims of its patents for the drug, citing the “difficulty, complexity and uncertainty” in assessing compensation under an undertaking as to damages in pharmaceutical patent proceedings.
E-retail giant Catch Group has settled a lawsuit against Kogan for alleging violating its “catch” trade marks and the consumer law through sponsored links on Google driven by phrases using the word “catch”.
IP services company QANTM has signaled the end to a bidding war to acquire rival Xenith IP, saying it will not match the terms of the latest offer lodged by fellow IP services provider IPH that would see it acquire Xenith outright.
US lingerie company Victoria’s Secret has reached a settlement in a lawsuit over the sale of knockoff products that mimic the get-up of its trade marked body care products.
F. Hoffman La-Roche has reached a settlement in a patent lawsuit over Sandoz’s plan to market a biosimilar version of its patented biologic used to treat various cancers and rheumatoid arthritis.